Cystic Fibrosis
📧 Sign up to get email alerts when something new happens for Cystic Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-10-02Clinical Trial Update: Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation [Phase 2]
Phase 2 trial evaluating lumacaftor/ivacaftor in cystic fibrosis patients with the A455E CFTR mutation; study completed with results posted …
-
CLINICAL_TRIALS trial_result · 2018-09-27Clinical Trial Update: A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation [Phase 4]
A Phase 4 pilot study evaluating smart adherence technology to measure lumacaftor/ivacaftor adherence in cystic fibrosis patients homozygous…
-
CLINICAL_TRIALS trial_result · 2018-09-06Clinical Trial Update: Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements [NA]
Clinical trial completion update evaluating high frequency chest wall oscillation vests on spirometry in cystic fibrosis and bronchiectasis;…
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis [Phase 1, Phase 2]
Phase 1/2 trial comparing inhaled xylitol to saline in stable cystic fibrosis patients; results posted after completion.
-
FDA approval · 2018-08-15FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for KALYDECO (ivacaftor) submitted by Vertex Pharmaceuticals Incorporated, resulting in updated …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-08-15FDA Approved: ORKAMBI — Supplemental Application (Vertex Pharmaceuticals Incorporated)
The FDA approved a supplemental application for ORKAMBI (lumacaftor and ivacaftor) submitted by Vertex Pharmaceuticals Incorporated.
-
FDA approval · 2018-08-15FDA Approved: KALYDECO — Supplemental Application (Vertex Pharmaceuticals Incorporated)
FDA approved a supplemental application for KALYDECO (ivacaftor) from Vertex Pharmaceuticals Incorporated.
-
CLINICAL_TRIALS trial_result · 2018-08-14Clinical Trial Update: SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis [Phase 3]
A Phase 3 trial update for SOLUTION study of an oral liprotamase unit-matched therapy in non-porcine origin for cystic fibrosis with exocrin…
-
CLINICAL_TRIALS trial_result · 2018-08-13Clinical Trial Update: Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis [Phase 2]
Phase 2 trial update on macrolide antibiotic therapy for patients with cystic fibrosis.
-
FDA approval · 2018-08-07FDA Approved: ORKAMBI — Original Application (Vertex Pharmaceuticals Incorporated)
The FDA approved ORKAMBI (lumacaftor and ivacaftor) under an original application for the treatment of cystic fibrosis. This marks the first…
-
CLINICAL_TRIALS trial_result · 2018-08-06Clinical Trial Update: An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations [Phase 3]
Phase 3 trial evaluating Ivacaftor in cystic fibrosis patients with two splicing mutations has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-08-06Clinical Trial Update: Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
A completed clinical trial evaluating the effects of mycophenolate mofetil in lung transplant recipients with cystic fibrosis; results poste…
-
CLINICAL_TRIALS trial_result · 2018-08-02Clinical Trial Update: Effect of Azithromycin on Fatty Acids in CF [Phase 4]
Phase 4 trial exploring the effect of azithromycin on fatty acids in cystic fibrosis patients.
-
CLINICAL_TRIALS withdrawal · 2018-07-31Clinical Trial Update: Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa [Phase 3]
A Phase 3 study evaluating Arikace for chronic Pseudomonas aeruginosa infection in Cystic Fibrosis patients has been withdrawn.
-
CLINICAL_TRIALS research · 2018-07-31Clinical Trial Update: Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis
Clinical trial update evaluating the real-world use of inhaled aztreonam lysine in cystic fibrosis patients.
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation [Phase 2]
Phase 2 trial evaluating VX-661/Ivacaftor in cystic fibrosis patients homozygous for F508del-CFTR; study completed with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: FDG-PET Imaging in Young Cystic Fibrosis Patients [NA]
A completed clinical trial update reports results from FDG-PET imaging in young patients with cystic fibrosis.
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study [NA]
A completed clinical trial evaluating absorption and safety with sustained use of RELiZORB in cystic fibrosis patients.
-
CLINICAL_TRIALS trial_result · 2018-07-17Clinical Trial Update: Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis. [Phase 1]
Phase 1 pharmacokinetic study assessing GLPG3067 in male subjects with cystic fibrosis.
-
CLINICAL_TRIALS trial_result · 2018-07-17Clinical Trial Update: The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis [NA]
A clinical trial update examining whether soluble fiber can reduce post-prandial glycemic excursions in adults with cystic fibrosis, includi…
-
CLINICAL_TRIALS trial_result · 2018-07-17Clinical Trial Update: Electrical Impedance Imaging of Patients With Cystic Fibrosis
Update on a ClinicalTrials.gov study investigating electrical impedance imaging in people with cystic fibrosis; the trial status is complete…
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis [Phase 1]
Phase 1 trial evaluated AZD5634 for effects on mucociliary clearance, safety, tolerability, and pharmacokinetics in patients with cystic fib…
-
CLINICAL_TRIALS trial_result · 2018-07-13Clinical Trial Update: Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability [NA]
Phase 2 trial evaluating ex-vivo lung perfusion and ventilation to assess transplant suitability, sponsored by the University of North Carol…
-
FDA approval · 2018-07-09FDA Approved: TOBRAMYCIN INHALATION SOLUTION — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved Dr. Reddy's Tobramycin Inhalation Solution as an original generic entry (ANDA 207080) for treating cystic fibrosis patients wit…
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis [Phase 2]
Phase 2 trial investigating andecaliximab in adults with cystic fibrosis has been terminated; results posted in 2018.